SOPHiA GENETICS SA $SOPH Stake Reduced by AIGH Capital Management LLC

Key Points

• AIGH Capital cut its SOPHiA GENETICS stake by 57.3% in the third quarter, selling 2,264,799 shares; it retained 1,689,395 shares, worth about $14.2 million.
• Analyst views are mixed: three rate the stock Buy, one Hold and one Sell, resulting in an average Hold rating and a $10 average price target.
• The company reported a quarterly loss of $0.24 per share, missing estimates by $0.04, while revenue of $24.27 million slightly exceeded expectations.

AIGH Capital Management LLC lessened its position in shares of SOPHiA GENETICS SA (NASDAQ:SOPH - Free Report) by 57.3% in the third quarter, according to its most recent filing with the SEC. The firm owned 1,689,395 shares of the company's stock after selling 2,264,799 shares during the quarter. SOPHiA GENETICS makes up approximately 1.4% of AIGH Capital Management LLC's investment portfolio, making the stock its 20th largest holding. AIGH Capital Management LLC owned approximately 2.01% of SOPHiA GENETICS worth $14,157,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of SOPH. Principal Financial Group Inc. raised its position in shares of SOPHiA GENETICS by 0.7% in the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company's stock worth $6,976,000 after acquiring an additional 9,800 shares in the last quarter. Royal Bank of Canada grew its stake in SOPHiA GENETICS by 3,130.2% during the first quarter. Royal Bank of Canada now owns 19,381 shares of the company's stock worth $96,000 after purchasing an additional 18,781 shares during the period. AXQ Capital LP acquired a new stake in SOPHiA GENETICS during the second quarter worth approximately $119,000. Hennion & Walsh Asset Management Inc. acquired a new stake in SOPHiA GENETICS during the second quarter worth approximately $567,000. Finally, Maven Securities LTD bought a new stake in SOPHiA GENETICS in the second quarter worth approximately $866,000. Institutional investors own 31.59% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. HC Wainwright reissued a "buy" rating and issued a $14.00 price target on shares of SOPHiA GENETICS in a research note on Monday, October 12th. BTIG Research raised their price objective on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a "buy" rating in a research report on Wednesday, August 5th. Zacks Research upgraded shares of SOPHiA GENETICS to a "hold" rating in a research note on Tuesday, July 21st. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research report on Thursday, October 15th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $10.00.

SOPHiA GENETICS Stock Performance

Shares of SOPHiA GENETICS stock opened at $6.62 on Friday. The business has a 50-day simple moving average of $7.74 and a 200 day simple moving average of $5.98. SOPHiA GENETICS SA has a one year low of $3.83 and a one year high of $8.98. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.29 and a quick ratio of 2.55. The firm has a market capitalization of $555.35 million, a price-to-earnings ratio of -6.07 and a beta of 1.09.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.04). SOPHiA GENETICS had a negative return on equity of 128.69% and a negative net margin of 89.18%. The firm had revenue of $24.27 million during the quarter, compared to the consensus estimate of $24.03 million. On average, research analysts anticipate that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Insider Buying and Selling at SOPHiA GENETICS

In other SOPHiA GENETICS news, insider Well Van sold 6,168 shares of the business's stock in a transaction on Monday, October 5th. The shares were sold at an average price of $8.12, for a total transaction of $50,084.16. Following the completion of the sale, the insider owned 332,716 shares in the company, valued at approximately $2,701,653.92. The trade was a 1.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Chairman Jurgi Camblong sold 8,500 shares of the company's stock in a transaction on Monday, October 12th. The stock was sold at an average price of $7.26, for a total transaction of $61,710.00. Following the transaction, the chairman owned 3,387,150 shares in the company, valued at approximately $24,590,709. The trade was a 0.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 170,662 shares of company stock worth $1,372,619 in the last ninety days. 4.88% of the stock is currently owned by corporate insiders.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a healthcare technology company that develops data-driven solutions for genomic medicine. Its cloud-based platform uses artificial intelligence, machine learning and advanced analytics to help healthcare organizations analyze and interpret complex biological and clinical data.

The company's primary offering, the SOPHiA DDM platform, supports next-generation sequencing workflows, including data management, quality control, genomic analysis, variant interpretation and reporting.

Want to see what other hedge funds are holding SOPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SOPHiA GENETICS SA (NASDAQ:SOPH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.